These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 20185277)
21. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. Cilli F; Aydemir S; Tunger A J Chemother; 2006 Feb; 18(1):27-32. PubMed ID: 16572890 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years. Appleman MD; Citron DM Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India. Dhawan B; Gadepalli R; Kapil A Diagn Microbiol Infect Dis; 2009 Oct; 65(2):196-8. PubMed ID: 19748433 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. Vouillamoz J; Moreillon P; Giddey M; Entenza JM J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. Barber KE; Smith JR; Raut A; Rybak MJ J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Sader HS; Streit JM; Fritsche TR; Jones RN Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289 [TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008). Sader HS; Becker HK; Moet GJ; Jones RN Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377 [TBL] [Abstract][Full Text] [Related]
28. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
29. Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. Cha R; Rybak MJ J Antimicrob Chemother; 2004 Jul; 54(1):259-62. PubMed ID: 15150172 [TBL] [Abstract][Full Text] [Related]
30. [Development of resistance in bacteria interacting with subinhibitory antibiotic concentrations]. Cokça F; Altay G Mikrobiyol Bul; 1992 Oct; 26(4):333-7. PubMed ID: 1435363 [TBL] [Abstract][Full Text] [Related]
31. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains. Paniagua GL; Monroy E; García O; Vaca S Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741 [TBL] [Abstract][Full Text] [Related]
32. [In vitro activity of daptomycin against VRE and MRSA strains]. Aktaş G; Derbentli S Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722 [TBL] [Abstract][Full Text] [Related]
33. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus. Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792 [TBL] [Abstract][Full Text] [Related]
34. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403 [TBL] [Abstract][Full Text] [Related]
35. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF; Chambers HF Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832 [TBL] [Abstract][Full Text] [Related]
36. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Pfaller MA; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2007 Apr; 57(4):459-65. PubMed ID: 17240105 [TBL] [Abstract][Full Text] [Related]
38. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp. Drago L; Nicola L; De Vecchi E Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336 [TBL] [Abstract][Full Text] [Related]
39. [False sensitivity of Enterococcus faecium to amoxicillin-clavulanic acid with the MicroScan system]. Joyanes P; Pascual A; Suárez AI; Martínez-Martínez L Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):96-8. PubMed ID: 7711133 [TBL] [Abstract][Full Text] [Related]
40. In vitro activity of vancomycin and daptomycin against clinical isolates of Staphylococcus aureus and enterococci from India. Jain S; Gaind R; Chugh TD Int J Antimicrob Agents; 2013 Jul; 42(1):94-5. PubMed ID: 23611307 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]